The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats.
Rapid, intravenous (i.v.) administration of high doses of bisphosphonates has been associated with acute renal toxicity. This controlled, preclinical study over 25 weeks investigated the potential for subclinical renal damage to accumulate to clinically relevant levels when minimally nephrotoxic doses of ibandronate (1 mg/kg) or zoledronate (1 or 3 mg/kg) were given intermittently, with a between-dose interval of 3 weeks, or as a single dose by i.v. injection. In rats, a single dose and intermittent dosing of ibandronate resulted in a similar incidence (one of six and two of six rats, respectively) and severity score (1.0 for both) of proximal tubular degeneration and single cell necrosis. No accumulation of histopathological renal damage occurred. However, intermittent dosing of zoledronate induced a higher incidence (six of six rats) and severity score (3.0) of renal damage compared with single dosing (four of six rats and 1.3, respectively). Accumulation of renal damage was also observed for a lower intermittent dose of zoledronate (1 mg/kg) that had not exhibited histopathological renal damage when given as a single 1 mg/kg dose. Biochemical parameters confirmed these histopathological findings. In summary, the results from this study indicate that administering ibandronate intermittently provides sufficient time for regeneration of potential subclinical renal damage.
Pfister
Thomas
T
Preclinical Research and Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland. thomas.pfister.tpl@roche.com
Atzpodien
Elke
E
Bauss
Frieder
F
D000117:Acetylglucosamine / Q000652:urine; D000818:Animals; D003404:Creatinine / Q000097:blood / Q000652:urine; D004164:Diphosphonates / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005982:Glutathione Transferase / Q000652:urine; D000077557:Ibandronic Acid; D007093:Imidazoles / Q000008:administration & dosage / Q000633:toxicity*; D007262:Infusions, Intravenous; D007674:Kidney Diseases / Q000139:chemically induced* / Q000473:pathology / Q000652:urine; D007770:L-Lactate Dehydrogenase / Q000652:urine; D051381:Rats; D017208:Rats, Wistar; D014508:Urea / Q000097:blood / Q000652:urine; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D014508:Urea; D003404:Creatinine; D007770:L-Lactate Dehydrogenase; D005982:Glutathione Transferase; D000077557:Ibandronic Acid; D000117:Acetylglucosamine